<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325402</url>
  </required_header>
  <id_info>
    <org_study_id>D2750C00002</org_study_id>
    <secondary_id>EudraCT # 2011-000095-34</secondary_id>
    <nct_id>NCT01325402</nct_id>
  </id_info>
  <brief_title>An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease</brief_title>
  <official_title>Open-Label Positron Emission Tomography Study With Selective Beta Amyloid Radioligand (18Fluor)AZD4694 to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study different mass of the radioligand AZD4694 will be given to patients with
      Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the
      best opportunities for following disease progress and treatment effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-Label Positron Emission Tomography Study with Selective Beta Amyloid Radioligand
      (18Fluor)AZD4694 to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding
      Parameters in Healthy Volunteers and Patients with Alzheimer's Disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Maximum Diagnostic Mass by assessing the visual read out of amyloid status according to and quantification of an [18F]AZD4694 PET image in a high mass experiment compared to the image in a low mass experiment in the same subject.</measure>
    <time_frame>Visit 3</time_frame>
    <description>Measuring the maximum chemical mass not causing any significant alteration of the amyloid status (unit = micrograms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum Diagnostic Mass by assessing the visual read out of amyloid status according to and quantification of an [18F]AZD4694 PET image in a high mass experiment compared to the image in a low mass experiment in the same subject.</measure>
    <time_frame>Visit 4</time_frame>
    <description>Measuring the maximum chemical mass not causing any significant alteration of the amyloid status (unit = micrograms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events as a measure of Safety and tolerability of [18F]AZD4694</measure>
    <time_frame>Range of Visits 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between early uptake of [18F]AZD4694 images and cerebral blood flow images as measured by Arterial Spin Labeling Magnetic resonance imaging</measure>
    <time_frame>Range of Screening Visit to Visit 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between estimates of β-amyloid load in brain obtained using [18F]AZD4694 Position Emission Tomography imaging and concentrations of β-amyloid in Cerebrospinal fluid</measure>
    <time_frame>Range of Screening Visit to Visit 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Maximum Diagnostic Mass of [18Fluor]AZD4694</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild to moderate Alzheimer's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[18Fluor]AZD4694</intervention_name>
    <description>Low mass dose below 5ug. High mass dose around 40 and 50 ug.</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[18Fluor]AZD4694</intervention_name>
    <description>Low mass dose below 5ug. High mass dose around 20 ug.</description>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[18Fluor]AZD4694</intervention_name>
    <description>Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index between 18 and 30 kg/m2 and weigh at least 50kg and no more than 100
             kg.

          -  Mini Mental State Examination score &gt;28 (healthy volunteers only)

          -  Mini Mental State Examination score 16-28 (Alzheimer's Disease patients only)

          -  Hachinski Ischemic Score =4 (Alzheimer's Disease patients only)

          -  Clinical diagnosis of probable Alzheimer's Disease according to National Institute of
             Neurology and Communicative Disorders and Stroke and the Alzheimer's Disease and
             Related Disorders Association criteria (Alzheimer's Disease patients only)

        Exclusion Criteria:

          -  Significant Neurological disease or dementia, as defined clinically or by imaging,
             other than Alzheimer's Disease that may affect cognition or ability to complete the
             study (Alzheimer's Disease patients only).

          -  Possible, probable or definite vascular dementia in accordance with the National
             Institute of neurology and Communicative Disorders and Stroke and the Alzheimer's
             Disease and Related Disorders association criteria (Alzheimer's Disease patients
             only).

          -  Current major depressive disorder or other major psychiatric disorders according to
             Diagnostic and Statistical Manual of Mental Disorders, edition 4, American Psychiatric
             Association 1994 criteria (Alzheimer's disease patients only).

          -  Depression: Cornell Depression Rating &gt;9 (Alzheimer's disease patients only).

          -  Abnormal vital signs defined as any of the following: Systolic blood pressure &gt;180
             mmHg, Diastolic blood pressure &gt;90 mmHg, heart rate &lt;40 or&gt;85 beats per minute
             (Alzheimer's disease patients only).

          -  Myocardial infarction or acute coronary syndrome within the last year (Alzheimer's
             disease patients only).

          -  Had Positron Emission Tomography measurements for scientific purposes within the last
             12 months.

          -  History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study
             (healthy volunteers only).

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs (healthy volunteers only).

          -  History of previous (within the last 5 years) or ongoing psychiatric disease/condition
             including psychosis, affective disorder, anxiety disorder, borderline state and
             personality disorder according to the criteria in to Diagnostic and Statistical Manual
             of Mental Disorders, edition 4, American Psychiatric Association 1994, as assessed by
             the Mini international neuropsychiatric interview (healthy volunteers only).

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of Investigational Product (healthy volunteers
             only).

          -  Any clinically significant abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the investigator (healthy volunteers only).

          -  Healthy volunteers&lt;65 years: abnormal vital signs defined as any of the following:
             Systolic blood pressure &gt;140 mmHg, Diastolic blood pressure &gt;90 mmHg, heart rate &lt;40
             or&gt;85 beats per minute.

          -  Healthy volunteers≥65 years: abnormal vital signs defined as any of the following:
             Systolic blood pressure &gt;160 mmHg, Diastolic blood pressure &gt;90 mmHg, heart rate &lt;40
             or &gt;85 beats per minute.

          -  Central Nervous system infarct, infection of focal lesions of clinical significance on
             MRI scans as judged by the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjorn Paulsson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels Andreasen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geriatric clinic Karolinska University Hospital Huddinge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabeth Eden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Aktiebolag</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radioligand</keyword>
  <keyword>Alzheimers disease</keyword>
  <keyword>Maximum Diagnostic Mass</keyword>
  <keyword>Beta amyloid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

